TALZENNA® updated

Pfizer Oncology is pleased to announce that the FDA has updated the Prescribing Information for TALZENNA® (talazoparib) on October 26, 2026 including new data with an expanded indication. The following information is available for State Society review:

• TALZENNA Full Prescribing Information including Medication Guide

If you have any questions, please contact me at your earliest convenience. If you don’t wish to receive emails like this from me in the future, please let me know by replying to this email.

View the Pfizer Privacy Policy here.

You are encouraged to report negative side effects related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088

PP-TXT-USA-0900